Compare SGHC & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | KRYS |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | SGHC | KRYS |
|---|---|---|
| Price | $11.99 | $248.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $16.00 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 2.5M | 326.2K |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 4925.62 | 275.72 |
| EPS | 0.45 | ★ 6.66 |
| Revenue | ★ $2,342,912,011.00 | $373,164,000.00 |
| Revenue This Year | $27.17 | $36.14 |
| Revenue Next Year | $10.88 | $41.80 |
| P/E Ratio | ★ $26.25 | $36.15 |
| Revenue Growth | 34.94 | ★ 54.51 |
| 52 Week Low | $5.45 | $122.80 |
| 52 Week High | $14.38 | $248.60 |
| Indicator | SGHC | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 73.35 |
| Support Level | $11.21 | $231.69 |
| Resistance Level | $12.06 | $248.60 |
| Average True Range (ATR) | 0.43 | 8.14 |
| MACD | 0.11 | -0.08 |
| Stochastic Oscillator | 92.75 | 99.48 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's reportable segments are Betway, Spin, and Other. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.